H.C. Wainwright analyst Matthew Caufield initiated coverage of Immunic (IMUX) with a Buy rating and $10 price target The firm likes the company’s “comprehensive” neuroprotective and anti-inflammatory approach to both relapsing and progressive multiple sclerosis. The positive Phase 3 ENSURE interim analysis “is de-risking in relapsing MS,” the analyst tells investors in a research note.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMUX:
- Immunic announces publication of IMU-856 data
- Immunic Reports Q3 Earnings and Provides Corporate Update
- Immunic, Inc. Advances MS Trials Amid Financial Update
- Immunic reports Q3 EPS (24c), consensus (22c)
- Is IMUX a Buy, Before Earnings?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
